Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) today reported positive three-month postoperative results from Group 1 patients in its first-in-human (FIH) clinical study of the Ocumetics Accommodating Intraocular Lens. The results validate the Company’s core technology and represent a key clinical de-risking milestone as Ocumetics advances toward subsequent study phases.
Group 1 data met or exceeded all predefined internal benchmarks for safety, lens delivery, and foundational distance visual performance. Patients with severe visual impairment, some presenting uncorrected preoperative acuities as poor as 20/250—consistent with legal blindness—experienced meaningful improvements in everyday vision post-implantation. Dr. Rafael Vázquez, principal investigator, stated that patients can now read, enjoy daily activities, and drive, describing the impact as life-changing.
“These first-in-human results are exactly what we were aiming to demonstrate at this stage: safe implantation, reliable delivery, and strong visual outcomes,” said Dean Burns, President and CEO of Ocumetics. “Following a detailed review of the data with Dr. Raphael Vasquez, our primary surgeon, I remain 100% confident in our accommodating intraocular lens technology. Based on this success, we have initiated planning for Group 2 surgeries.”
The Company has already implemented refinements to the lens delivery mechanism and initiated multiple lens optimization initiatives based on insights from Group 1. Manufacturing and testing of optimized lens designs are underway, with Group 2 surgeries expected after final lens testing and validation.
Ocumetics will host a webinar on Wednesday, February 4, 2026, at 4:00 PM ET to discuss the results. Interested parties can register at www.ocumetics.com/webinar.
About Ocumetics: Ocumetics Technology Corp. is a Canadian research and product development company dedicated to developing advanced vision correction solutions. The Ocumetics Lens is designed to fit within the eye’s natural lens compartment and use the eye’s natural muscle activity to shift focus from distance to near, potentially eliminating the need for corrective lenses. More information is available at www.ocumetics.com.
